Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study

Auvray M., Elaidi R., Ozguroglu M., Guven S., Gauthier H., Culine S., ...More

CLINICAL GENITOURINARY CANCER, vol.15, no.3, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.1016/j.clgc.2016.10.013
  • Journal Name: CLINICAL GENITOURINARY CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Biomarker, Inflammation, Overall survival, Prognostic value, Progression-free survival, TRANSITIONAL-CELL CARCINOMA, GEMCITABINE PLUS CISPLATIN, LONG-TERM-SURVIVAL, PRETREATMENT NEUTROPHIL, PREDICTING SURVIVAL, RADICAL CYSTECTOMY, BLADDER-CANCER, INFLAMMATION, CARBOPLATIN, OUTCOMES
  • Istanbul University-Cerrahpasa Affiliated: No

Abstract

This multicenter study assessed the prognostic value of the neutrophile-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, for overall survival (OS) and progression-free survival (PFS) after first-line chemotherapy (CT) in 280 metastatic urothelial cancer patients. High pre-CT NLR was an independent predictor of reduced of OS (hazard ratio=1.36; P<.0001), highlighting the importance of an inflammatory cancer-related microenvironment.